v3.26.3
Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
                 
Research and development  $42,823   $27,630   $83,047   $96,848 
General and administrative   31,271    25,626    114,590    92,615 
                     
Total  $74,094   $53,256   $197,637   $189,463 
Schedule of Key Assumption of Fair Value of Stock Options Granted

For options granted during each of the nine months ended September 30, 2026 and 2025, the Company calculated the fair value of each option grant on the respective dates of grant using the following weighted average assumptions:

 

   2026   2025 
Expected term   5.83 years    5.73 years 
Risk-free interest rate   4.05%   4.30%
Expected dividend yield   —    — 
Expected volatility   91.02%   94.19%
Schedule of Stock Option Activity

A summary of stock option activity is as follows:

 

   Outstanding stock options 
   Number of shares   Weighted average exercise price 
Balance at December 31, 2024   335,258   $23.59 
Options granted   100,994    4.22 
Options exercised   -    - 
Options forfeited   (8,327)   4.62 
Options cancelled   (10,616)   48.83 
Balance at December 31, 2025   417,309    18.64 
Options granted   99,073    4.61 
Options exercised   (1,325)   5.27 
Options forfeited   (28,913)   90.53 
Options cancelled   (5,966)   3.66 
Balance at September 30, 2026   480,178    11.64 
           
Options exercisable at September 30, 2026   278,812    16.81 
Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable:

 

As of September 30, 2026
Options outstanding  Options exercisable

Number

outstanding

   

Weighted

average

remaining

contractual

life

(Years)

    

Weighted

average exercise

price

    

Aggregate

intrinsic value

  

Number

exercisable

   

Weighted

average

remaining

contractual life

(Years)

    

Weighted

average

exercise

price

    

Aggregate

intrinsic value

 
                                  
480,178   6.87   $11.64   $233   278,812   5.15   $16.81   $- 

 

As of September 30, 2025
Options outstanding  Options exercisable

Number

outstanding

 

Weighted

average

remaining

contractual

life (Years)

  

Weighted

average

exercise price

  

Aggregate

intrinsic value

  

Number

exercisable

 

Weighted

average

remaining

contractual life

(Years)

  

Weighted

average

exercise

price

  

Aggregate

intrinsic value

 
                                  
348,497   6.19   $21.57   $-   262,754   5.25   $27.08   $- 
Summary of Restricted Stock Unit Activity

A summary of restricted stock unit activity is as follows:

 

   Number of Unvested Restricted Stock Units 
     
Balance at December 31, 2025   18,137 
Granted   - 
Vested   (2,418)
Cancelled   - 
Balance at September 30, 2026   15,719